Sweetman R W, Cairo M S
Children's Hospital of Orange County, Orange, CA 92668, USA.
Transfus Med Rev. 1995 Jul;9(3):251-9. doi: 10.1016/s0887-7963(05)80113-0.
The future role of IVIG remains unclear. Many, but not all, studies indicate efficacy in the prevention of late-onset disease in premature infants. The role of type-specific IVIG is evolving and may hold promise for both prevention and treatment of neonatal sepsis. Granulocyte transfusions, as adjuvant therapy in neonatal sepsis, seem to be beneficial. However, the difficulty and expense of collection, as well as the advent of colony-stimulating factors, have shifted the focus away from their routine use. Colony-stimulating factors present varied and exciting potential uses, including modulating neonatal hematopoiesis. Current studies are primarily aimed at understanding their effects on neonatal hematopoiesis. Future studies will need to expand on this knowledge and examine what effects they have on treating or preventing neonatal sepsis.
静脉注射免疫球蛋白（IVIG）的未来作用仍不明确。许多（但并非所有）研究表明其在预防早产儿晚发型疾病方面有效。特异性IVIG的作用正在不断演变，可能在预防和治疗新生儿败血症方面具有前景。粒细胞输注作为新生儿败血症的辅助治疗似乎有益。然而，采集的困难和费用，以及集落刺激因子的出现，已使人们不再将常规使用粒细胞输注作为重点。集落刺激因子具有多样且令人兴奋的潜在用途，包括调节新生儿造血。目前的研究主要旨在了解它们对新生儿造血的影响。未来的研究需要在此基础上进一步拓展，研究它们对治疗或预防新生儿败血症有何作用。
